Marlene Wang, MS

Cabenuva, the combination of cabotegravir, a 

 integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), works by decreasing HIV concentrations in the blood.

 (cabotegravir 200 mg/mL and rilpivirine 300 mg/mL) as a once-monthly treatment for HIV-1 infected adults who are virologically suppressed (HIV-1 RNA ≤ 50 copies/mL [c/mL]) on a stable antiretroviral regimen.

Eligible patients must have no history of treatment failure and no known or suspected resistance to cabotegravir or rilpivirine.

 In the phase 2 and 3 randomized trials, researchers showed the monthly injectable combination had comparable results with current daily oral antiretroviral regimens.

The FDA recently approved the extended label to be administrated every 2 months based on non-inferiority trial data.

 In the phase 3b study, researchers randomized 1045 participants to receive either cabotegravir 600 mg/rilpivirine 900 mg every 8 weeks or cabotegravir 400 mg/rilpivirine 600 mg every 4 weeks.

The primary endpoint was the proportion of patients with HIV RNA ≥ 50 c/mL at week 48 between 2 groups with a non-inferiority margin of 4%.

 Dosing every 8 weeks and dosing every 4 weeks resulted in similar efficacy.

The researchers identified an RNA ≥ 50 c/mL in 2% of the every 8-weeks group and 1% in the every 4-weeks group. The every 8-weeks group experienced 2% confirmed virological failures (CVF; 2 sequential measures ≥200 c/mL), whereas that figure was 1% in the every 4-weeks group.

Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for the HIV replication cycle. Rilpivirine is a diarylpyrimidine NNRTI of HIV-1 and inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.

Before initiating treatment, health care providers (HCP) should address the importance of adherence and carefully select patients who agree to the dosing schedule. Prior to injection, prescribers should initiate patients on daily oral lead-in with 30 mg cabotegravir and 25 mg rilpivirine with a meal for 1 month to assess the tolerability.

Clinicians should administer cabotegravir/rilpivirine (which are co-packaged) as a gluteal intramuscular injection at separate injection sites (on opposite side or 2 cm apart).

On the last day of oral lead-in, clinicians should administer 600 mg (3 mL) of cabotegravir and 900 mg (3 mL) of rilpivirine. The following monthly injections are lower doses of 400 mg (2 mL) of cabotegravir and 600 mg (2 mL) of rilpivirine.

On the last day of oral lead-in, clinicians should administer 600 mg (3 mL) of cabotegravir and 900 mg (3 mL) of rilpivirine 1 month apart for 2 consecutive months. Then, continue the following injections every 2 months with same dosage.

From monthly to every 2-month: Clinicians should administer an injection 1 month after the last monthly injection and then every 2 months injections thereafter.

From every 2-month to monthly: Clinicians should administer an injection 2 months after the last every 2-month injections and then monthly thereafter.

Planned missing dose by more than 7 days: After 1 month (monthly injection schedule) or 2 months (2-months injection schedule) from the last injection, start daily oral cabotegravir 30 mg and rilpivirine 25 mg with a meal for up to 2 months.

The most common adverse reactions are injection site reactions, pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash.

Hypersensitivity reactions with rilpivirine-containing regimens have been reported. Serious post-injection reactions with rilpivirine were reported.

If patients experience dyspnea, bronchospasm, agitation, abdominal cramping, rash/urticaria, dizziness, flushing, sweating, oral numbness, changes in blood pressure, and pain (e.g., back and chest), the prescriber should stop the medication. Hepatotoxicity has been reported in patients receiving cabotegravir or rilpivirine with or without known pre-existing hepatic disease or identifiable risk factors. The approved product labeling recommends monitoring liver chemistries.

Disorders include depressed mood, depression, major depression, mood altered, mood swings, dysphoria, negative thoughts, and suicidal ideation or attempt have been reported with this combination product and the individual drug products. The approved product labeling recommends prompt evaluation for depressive symptoms.

Residual cabotegravir and rilpivirine may remain in patients’ systemic circulation for 12 months or longer after discontinuation. Initiate an alternative antiretroviral regimen no later than 1 month after the final injections of Cabenuva when dosed monthly and no later than 2 months after the final injections when dosed every 2 months to avoid waning virologic response and resistance development. Use an alternative regimen if virologic failure is suspected.

Researchers have insufficient human data on the use of cabotegravir/rilpivirine during pregnancy and long-lasting residual cabotegravir/rilpivirine in patients’ systemic circulation to make a recommendation.

The Centers for Disease Control and Prevention doesn’t recommend breastfeeding for patients with HIV.

, is a research scientist in the pharmaceutical industry

CABENUVA [product information]. Research Triangle Park, NC: ViiV healthcare; February 2022. Accessed March 7, 2022.

ONCE-MONTHLY CABENUVA CLINICAL TRIAL. Viiv healthcare. 

https://cabenuvahcp.com/efficacy/atlas-flair/

ViiV HEALTHCARE ANNOUNCES US FDA APPROVAL OF 

 (CABOTEGRAVIR, RILPIVIRINE) FOR USE EVERY TWO MONTHS, EXPANDING THE LABEL OF THE FIRST AND ONLY COMPLETE LONG-ACTING HIV TREATMENT. Viiv healthcare. 

https://viivhealthcare.com/en-us/media-center/news/press-releases/2022/january/viiv-healthcare-announces-us-fda-approval-of-cabenuva/

Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. 

. 2021;396(10267):1994-2005. doi:10.1016/S0140-6736(20)32666-0

Articles

Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration.

Clinical Overview: Cabenuva for HIV

Cabenuva, the combination of cabotegravir, an 

 integrase strand transfer inhibitor, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), works by decreasing HIV concentrations in the blood. The 

 (cabotegravir 200 mg/mL and rilpivirine 300 mg/mL) as a once-monthly treatment for adults with HIV-1 who are virologically suppressed (HIV-1 RNA ≤ 50 copies/mL [c/mL]) on a stable antiretroviral regimen.

 In the phase 2 and 3 randomized trials, researchers showed the monthly injectable combination had comparable results with current daily oral antiretroviral regime.

 In the phase 3b study, researchers randomized 1045 participants to receive either cabotegravir 600 mg/rilpivirine 900 mg every 8 weeks or cabotegravir 400 mg/rilpivirine 600 mg every 4 weeks. 

Dosing every 8 weeks and dosing every 4 weeks resulted in similar efficacy. 

Clinicians should administer cabotegravir/rilpivirine, which are co-packaged, as a gluteal intramuscular injection at separate injection sites, on opposite side or 2 cm apart.

On the last day of oral lead-in, clinicians should administer 600 mg (3mL) of cabotegravir and 900 mg (3 mL) of rilpivirine 1 month apart for 2 consecutive months. Then, continue the following injections every 2 months with same dosage.

: Clinicians should administer an injection 1 month after the last monthly injection and then every 2 months injections thereafter.

: Clinicians should administer an injection 2 months after the last every 2-month injections and then monthly thereafter.

The most common AEs are injection site reactions, pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash.

Hypersensitivity reactions with rilpivirine-containing regimens have been reported, as have serious post-injection reactions with rilpivirine. If patients experience dyspnea, bronchospasm, agitation, abdominal cramping, rash/urticaria, dizziness, flushing, sweating, oral numbness, changes in blood pressure, and pain (e.g., back and chest), the prescriber should stop the medication.

Hepatotoxicity has been reported in patients receiving cabotegravir or rilpivirine with or without known pre-existing hepatic disease or identifiable risk factors. The approved product labeling recommends monitoring liver chemistries.

Disorders include depressed mood, depression, major depression, altered mood, mood swings, dysphoria, and negative thoughts. Suicidal ideation or attempts been reported with this combination product and the individual drug products. The approved product labeling recommends prompt evaluation for depressive symptoms.

Researchers have insufficient human data on the use of cabotegravir/rilpivirine during pregnancy and long-lasting residual cabotegravir/rilpivirine in patients’ systemic circulation to make a recommendation. The Centers for Disease Control and Prevention doesn’t recommend breastfeeding for patients with HIV.

Marlene Wang, MS, is a research scientist in the pharmaceutical industry

ONCE-MONTHLY CABENUVA CLINICAL TRIAL.Viiv healthcare. 

The FDA recently approved cabotegravir 200 mg/mL and rilpivirine 300 mg/mL as a once-monthly treatment for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen.